New EU regulation on health technology assessment of cancer medicines

Lancet Oncol. 2022 Feb;23(2):e58. doi: 10.1016/S1470-2045(22)00008-0.

Authors

Thomas J Hwang¹, Kerstin N Vokinger²

Affiliations

¹ Institute of Law and Laboratory for Technology, Markets, and Regulation, University of Zurich, Zurich 8001, Switzerland.
² Institute of Law and Laboratory for Technology, Markets, and Regulation, University of Zurich, Zurich 8001, Switzerland. Electronic address: kerstinnoelle.vokinger@usz.ch.

PMID: 35114127
DOI: 10.1016/S1470-2045(22)00008-0

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents*
Drug and Narcotic Control*
European Union
Humans
Technology Assessment, Biomedical / legislation & jurisprudence*

Substances

Antineoplastic Agents